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Narcolepsy type 1, likely an immune-mediated disease, is characterized by excessive daytime sleepiness and
cataplexy. The disease is strongly associated with human leukocyte antigen (HLA) DQB1*06:02. A significant
increase in the incidence of childhood and adolescent narcolepsy was observed after a vaccination campaign with
AS03-adjuvanted Pandemrix influenza vaccine in Nordic and several other countries in 2010 and 2011. Previ-
ously, it has been suggested that a surface-exposed region of influenza A nucleoprotein, a structural component of
the Pandemrix vaccine, shares amino acid residues with the first extracellular domain of the human OX2 orexin/
hypocretin receptor eliciting the development of autoantibodies. Here, we analyzed, whether H1N1pdm09
infection or Pandemrix vaccination contributed to the development of autoantibodies to the orexin precursor
protein or the OX1 or OX2 receptors. The analysis was based on the presence or absence of autoantibody responses
against analyzed proteins. Entire OX1 and OX2 receptors or just their extracellular N-termini were transiently
expressed in HuH7 cells to determine specific antibody responses in human sera. Based on our immunofluores-
cence analysis, none of the 56 Pandemrix-vaccinated narcoleptic patients, 28 patients who suffered from a
laboratory-confirmed H1N1pdm09 infection or 19 Pandemrix-vaccinated controls showed specific autoantibody
responses to prepro-orexin, orexin receptors or the isolated extracellular N-termini of orexin receptors. We also
did not find any evidence for cell-mediated immunity against the N-terminal epitopes of OX2. Our findings do not
support the hypothesis that the surface-exposed region of the influenza nucleoprotein A would elicit the devel-
opment of an immune response against orexin receptors.Authors’ contributions
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1. Introduction
Narcolepsy, divided in two different disease subcategories, is a
chronic neurological disorder of hypersomnolence. The main symptoms
of narcolepsy type 1 (NT1) are excessive daytime sleepiness, cataplexy
and disturbed nocturnal sleep. Patients may also have rapid eye move-
ment sleep-related symptoms such as hypnagogic hallucinations andnkatu 10, 20520, Turku, Finland.
nen).
ril 2020
rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
K. Melen et al. Journal of Translational Autoimmunity 3 (2020) 100055sleep paralysis [1,2]. In general, NT1 starts during the adolescence or
young adulthood, and disease onset before the age of 10 years has been
rare [3–5]. NT1 is strongly associated with human leukocyte antigen
(HLA) class II DQB1*06:02 [6,7]. An immune-mediated neuronal
destruction, resulting in a deficit in the endogenous orexin (also called
hypocretin) production in the lateral hypothalamus, is considered to be
the primary pathophysiological mechanism of NT1 [8–11]. The onset of
NT1 has been shown to be seasonal, and in some studies NT1 has been
associated with upper respiratory tract infections, such as H1N1 influ-
enza A virus infection [12] and/or streptococcal infections [13,14]. ThisFig. 1. Peptide epitopes of interest for the current study. (A) Orexin-A and orexin-B
contains an N-terminal signal peptide. Orexin-A contains two disulfide bridges. (B) Or
46-amino acid-long and OX2 a 54-amino acid-long N-terminus. The potential cross-r
shown in yellow. (D) An alignment of human OX1 and OX2 receptors and the influen
consensus sequences between influenza NP and orexin receptors (identical amino a
positions of the amino acids are as indicated in the figure.
2
suggests that these infections could initiate an immune response that
leads to the loss of orexin-secreting neurons in hypothalamus and the
development of clinical NT1. Etiologically unknown narcolepsy type 2 is
characterized by normal central nervous system orexin levels and
absence of cataplexy.
Biologically active orexin peptides are produced by the cleavage of
the 131-amino acid-long orexin precursor protein (prepro-orexin/pre-
prohypocretin) into two smaller peptides: a 33-amino acid-long orexin-
A/hypocretin 1 with two intrachain disulfide bonds and a 28-amino acid-
long orexin-B/hypocretin 2 (Fig. 1). Prepro-orexin is produced in theare cleaved from their 131-amino acid-long precursor prepro-orexin that also
exin receptors are transmembrane proteins located on cell surface. (C) OX1 has a
eactive epitopes between OX1 and OX2 receptors and influenza A virus NP are
za nucleoprotein (X-181 reassortant vaccine) used in Pandemrix vaccine show a
cids are marked in large bold) (Adapted from Ahmed et al., 2015 [28]). The
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neuronal cells. Orexin peptides act via two G-protein-coupled orexin
receptors OX1 and OX2 [15]. OX1 and OX2 are 425- and 444-amino
acid-long transmembrane receptors that have 46- and 54-amino
acid-long N-terminal extracellular domains, respectively, followed by
seven transmembrane regions, three intra- and three extracellular loops,
and relatively short cytoplasmic tails (Fig. 1). The dual orexin/hypocretin
nomenclature originates from the parallel discovery of the system by two
different groups [15,16]. According to the current recommendations,
which are followed in this paper, the peptides are to be called with the
orexin nomenclature while the genes follow the hypocretin nomencla-
ture (HCRT for the human peptide and HCRTR1 and HCRTR2 for the
receptors).
Increased incidence of NT1 was observed in Finland, Sweden and
France after vaccination of the general population with Pandemrix vac-
cine in 2009 [5,17–19]. Later, increased incidence of narcolepsy was also
found in Norway, the United Kingdom, Ireland and Germany [20–23]. It
has been suggested that vaccination with AS03-adjuvanted Pandemrix
vaccine, in the absence or possibly together with some other environ-
mental factors, contributed to a 5 to 14-fold increased incidence of nar-
colepsy in HLA DQB1*06:02-positive children and adolescents and the 2-
to 7-fold increased incidence in adults [24].
The pH1N1-like vaccine strain X-179 A, used in the production of
Pandemrix vaccine, was created as a reassortant virus using an H1N1-
1918-like strain, A/Puerto Rico/8/1934 (PR8), as a backbone vaccine
virus. Hemagglutinin (HA), neuraminidase (NA) and polymerase protein
1 (PB1) genes were derived from A/California/07/2009 virus and the
remaining five viral genes from the PR8 virus [25–27]. Previously, it has
been suggested that an epitope of the surface of influenza A PR8 virus
nucleoprotein, used in Pandemrix, shows molecular mimicry with the
extracellular N-terminus of the OX2 receptor [28]. It was hypothesized
that this would trigger autoantibody formation and an immune-mediated
neuronal destruction, resulting in a deficit in the endogenous orexin
production in vaccinated HLA DQB1*06:02-positive children and ado-
lescents [28].
There is controversial information in the literature whether narco-
leptic patients have autoantibodies against orexin receptors [28–31].
Therefore, we analyzed whether Pandemrix-vaccinated narcoleptic
children and adolescents and control individuals as well as patients who
suffered a laboratory confirmed H1N1pdm09 virus infection have auto-
antibodies against human orexin or OX1 and OX2 receptors.
In this study, using an immunofluorescence microscopy assay (IFA),
we analyzed human sera collected from 56 Pandemrix-vaccinated
narcoleptic patients; 28 patients, who suffered from a laboratory-
confirmed H1N1pdm09 infection; and 19 Pandemrix-vaccinated con-
trols. Cell-mediated immunity against peptides derived from the N-ter-
minus of the OX2 receptor was also analyzed in 6 NT1 patients and 5
Pandemrix-vaccinated controls. Our findings do not support the hy-
pothesis that influenza H1N1pdm09 infection or vaccination with the
Pandemrix vaccine induced cross-reactive autoantibodies or T cells
against influenza A virus nucleoprotein (NP) and the N-terminus of OX2.
2. Materials and methods
2.1. Ethical permissions
The study protocol was approved by the Institutional Review Board of
the National Institute for Health and Welfare (THL), Helsinki, Finland,
and the Ethics committee of the Helsinki and Uusimaa Health District
(permission code number 331/13/March 03, 2010) covering the
participating hospitals. The collection of blood samples from narcoleptic
children and Pandemrix-vaccinated controls have been previously
described [32,33]. Informed written consent was given by the children
and/or their guardians.
The collection of blood samples from individuals suffering from an
upper respiratory tract infection was approved by the Ethics Committee3
of the Pirkanmaa Hospital District, Tampere, Finland (ETL-code numbers
R09152 M and R10075 M). All patients gave their written informed
consent for blood samples. The studies fully comply with the national and
international regulations, privacy and data protection relevant to medical
and patient-oriented studies.2.2. Identification of narcoleptic patients
The present study comprises 56 narcoleptic patients aged 5–18 years
at the onset who fell ill in 2009 or 2010 after receiving Pandemrix vac-
cine in November or December 2009. The description of the patients, the
date of Pandemrix vaccination, time of the onset of narcolepsy and the
time of serum sample collection have been previously described [17,
32–34]. The diagnosis of narcolepsy with cataplexy was based on the
2005 version of International Classification of Sleep Disorders (ICSD-2)
[1]. All our diagnoses have been later reclassified into type 1 narcolepsy
(ICD-10 code G47.4) according to the current (ICSD-3) version of the
classification [35]. A polysomnography and Multiple Sleep Latency Test
(MSLT) and HLA DQB1 genotyping with a panel of sequence-specific
oligonucleotide probes [36] were carried out for each patient. If the
diagnosis of narcolepsy with cataplexy was not clear, also a lumbar
puncture was done with analysis of cerebrospinal fluid orexin-levels ac-
cording to the Stanford RIA protocol to verify the diagnosis. Other causes
of excessive daytime sleepiness (EDS) (e.g. sleep apnea, delayed sleep
phase syndrome or sleep deprivation) as well as other neurological dis-
orders (encephalitis, encephalopathy, other neurological disorders) were
excluded by polysomnography, actigraphy, thorough neurological ex-
amination, magnetic resonance imaging (MRI), electroencephalography
(EEG), cerebrospinal fluid (CSF) examinations, blood tests, and other
examinations when necessary. Based on the review of patient records, an
experienced neurologist and a sleep specialist (Drs. Markku Partinen and
Turkka Kirjavainen), independently of each other, validated the time of
onset and diagnosis of narcolepsy. If the opinion of the two specialists
differed significantly, the onset time and diagnosis was verified by a
panel of three neurologists/sleep specialists (alternating Drs. C. Hublin,
O. Saarenp€a€a-Heikkil€a, P. Olsen and S.-L. Himanen).2.3. Blood samples from narcoleptic patients and from healthy controls
Blood specimens from all 56 narcoleptic patients and 19 control in-
dividuals were collected during 2011. Paired serum specimens from 28
adults suffering from a clinical, laboratory-confirmed H1N1pdm09 virus
infection were collected during the epidemic seasons 2009–2010 and
2010–2011 in Tampere, Finland. H1N1pdm09 infection was confirmed
by identifying viral RNA in nasopharyngeal stick samples collected dur-
ing the acute phase of the disease using a diagnostic polymerase chain
reaction test with the NS gene as the target [37]. Five of the 28 patients
had previously been vaccinated with Pandemrix vaccine.
Paired serum specimens were collected at the acute and convalescent
phases (14–21 days later) of the disease. All patients showed a diagnostic
antibody rise in the H1N1pdm09 virus-specific hemagglutination inhi-
bition assay (HI;  4  rise) or H1N1pdm09 NS1 protein-specific West-
ern blot assay (2  rise) [33].2.4. Patient and healthy control donor material in the T cell study
The T cell study included 6 pediatric Pandemrix-associated NT1 pa-
tients and 5 healthy Pandemrix-vaccinated control children or adoles-
cents. NT1 patients were diagnosed in neurological outpatient clinics at
Finnish hospitals and health care centers by neurologists with expertise
in sleep medicine. All patients were diagnosed with NT1 based on criteria
defined in the 3rd edition of the International classification of sleep
disorders [35].
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Human hepatocellular carcinomaHuH7 [38] cells weremaintained in
continuous culture in minimum essential medium (MEM) (Thermo Fisher
Scientific Inc., Waltham, MS, USA) supplemented with 0.6 μg/ml peni-
cillin, 60 μg/ml streptomycin and 10% fetal calf serum (Sigma-Aldrich
Co. LLC., St. Louis, MO, USA). Spodoptera frugiperda 9 (Sf9) cells were
used for baculovirus expression and maintained in TNM-FH (Sigma-Al-
drich) medium as described previously [39]. To collect human peripheral
blood mononuclear cells (PBMC), whole blood was drawn and heparin-
ized. PBMCs cells were isolated by Ficoll gradient centrifugation (GE
Healthcare, Uppsala, Sweden) and stored in liquid nitrogen until further
analysis.
2.6. T cell peptides
Five peptides covering the amino acid sequence of the human OX2
from amino acid positions 27 to 53 (Fig. 1) were produced, including the
core peptide DYDDEEFLRYLWREY (15-mer peptides, 12 amino acids
overlap; New England Peptides, Gardner, MA, USA). The peptides were
dissolved in endotoxin-free water/DMSO (50%; both from Sigma-Aldrich
Co.) and stored as 25 mM stock at 70 C, until the day of use.
2.7. PBMC stimulation experiments
Frozen PBMCs were thawed and allowed to recover in RPMI 1640
culture medium (Thermo Fisher Scientific Inc.) containing 2 mM L-
glutamine, 25 mMHEPES, 25 μg/ml gentamycin (Sigma-Aldrich) and 5%
of heat-inactivated serum from AB-negative individuals (Innovative
Research, Novi, MI, USA) at 37 C in a CO2 incubator for 1 h. The cells
were stimulated with the 15-mer peptides based on the N-terminus of the
OX2 receptor (10 μM each; resulting DMSO concentration 0.1%), tetanus
toxoid (20 μg/ml), or PBS (negative control) for 6 days.
2.8. Antibodies and immunofluorescence (IFA)
For immunofluorescence microscopy, studied human sera, rabbit
polyclonal anti-OX2 immunoglobulins (AB3094; EMD Millipore Corp.,
Temecula, CA, USA), primary mouse monoclonal anti-His immunoglob-
ulins (sc-53073; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
rabbit anti-influenza A/PR/8/34 virus NP were diluted 1:25 and 1:100
(patient sera), 1:200 (anti-OX2), 1:200 (anti-His) or 1:250 (anti-NP) into
0.5% bovine serum albumin (BSA) in PBS and incubated at 4 C over-
night. Influenza A NP was produced in E. coli; the method for antibody
production has been described previously [40]. Secondary Texas
Red-labeled goat anti-human (Vector, Vector Laboratories, Inc., Burlin-
game, CA, USA), rhodamine-labeled goat anti-rabbit (#111-026-047,
Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) and
fluorescein-labeled goat anti-mouse (#116-095-003, Jackson Immu-
noResearch Laboratories) immunoglobulins were used according to the
manufacturers’ instructions. After washing, the glass coverslips were
mounted on Mowiol (Sigma-Aldrich Co.) and images were taken with
Leica TCS NT confocal microscope.
2.9. Plasmids and DNA manipulations
The OX1-GFP baculovirus expression vector has been described pre-
viously [41]. The OX2-GFP baculovirus was constructed in the same way
by Drs. Johnny N€asman (Åbo Akademi University, Turku, Finland) and
Jaana Putula (University of Helsinki) from the OX2-GFP sequence as
described in Ref. [42].
For the creation of OX1-and OX2-GFP-V5-His as well as OX1-and OX2-
GFP expression constructs, cDNAs coding for the human OX1 and OX2
receptors [42] were first digested with BsrGI, blunted by Klenow frag-
ment fill-in and then digested with HindIII. The fragments were ligated
into pcDNA3.1/V5-His TOPO (Invitrogen) digested with HindIII–EcoRV.4
Synthetic genes coding for the N-termini of the human OX1 (amino
acids 1–46; cDNA of HCRTR1: NM_001525.2) and OX2 receptors (amino
acids 1–54; cDNA of HCRTR2: NM_001526.4) and the full-length prepro-
orexin (amino acids 1–131; cDNA of HCRT: NM_001524.1) were ordered
from GenArt (Thermo Fisher Scientific Inc.). The 50-ends were modified
by adding a BglII/BamHI restriction site and a Kozak consensus sequence,
ACC, prior to the translation start sites (AGA TCT GGA TCC ACC ATG,
initiation codon underlined). To the 30-ends of the cDNAs, a second BglII/
BamHI site, without a stop codon, was added, enabling the subcloning of
the genes into the BamHI site of the eukaryotic expression vector
pcDNA3.1 ()A-myc-His (Invitrogen).
Influenza A/WSN/33 NP (accession number: CY034135.1) gene was
modified by PCR to create 50 and 30 BamHI sites and an N-terminal Kozak
consensus sequence for its further cloning into the eukaryotic expression
vector pcDNA3.1 (þ) (Thermo Fisher Scientific Inc.).
All DNA manipulations were performed according to standard pro-
tocols, and the newly created gene constructs were fully sequenced.
2.10. Production of OX1-GFP- and OX2-GFP-expressing baculoviruses
Three days after infecting Sf9 cells with OX1-GFP- and OX2-GFP-
expressing baculoviruses, cell medium was collected and centrifuged in
2 ml tubes at 12 000 rpm for 30 min. Supernatants were collected and
baculovirus stocks were diluted in 1:10 volume of EMEM supplemented
as mentioned above. For further transduction experiments, baculoviruses
were stored at 4 C.
2.11. Transduction and transfection of HuH7 cells
HuH7 cells were first transduced for 1 h with OX1-GFP- and OX2-GFP-
expressing baculoviruses in EMEM supplemented with 2% fetal calf
serum, followed by removal of the viruses and addition of fresh growth
medium supplemented as above. Alternatively, HuH7 cells were grown
on glass coverslips for 24 h and then transfected with expression plasmids
(expressing OX1-GFP-V5-His, OX2-GFP-V5-His, OX1 (1–46)-myc-His, OX2
(1–54)-myc-His, prepro-HCRT-myc-His or influenza A/WSN/33 NP)
using TransIT®–LT1 transfection reagent (Mirus Bio Corp., Madison, WI,
USA) according to the manufacturer’s instructions. At 24 h post trans-
duction/transfection, the cells were fixed with 3% paraformaldehyde in
PBS for 30 min, permeabilized with 0.1% Triton X-100 in PBS for 15 min
and blocked with 0.5% BSA in PBS at RT for 30 min.
2.12. Enzyme immunoassay (EIA), antigens and statistical analysis
Production of GST and GST-NP (A/PR/8/34) has been described
elsewhere [40]. H1N1 antigen suspension of Pandemrix (GlaxoSmithK-
line, Dresden, Germany) vaccine was concentrated with Vivaspin 10 K
PES membrane filters (Sartorius, Darmstadt, Germany).
Influenza A nucleoprotein or H1N1 vaccine virus-specific antibody
EIA was done as described before [43]. Briefly, 96-well microtiter plates
(Nunc Maxisorp, Thermo Fisher Scientific Inc.) were coated with 0.5
μg/ml of GST, 1.5 μg/ml of GST-NP and 1.0 μg/ml of H1N1 antigen
suspension of Pandemrix vaccine in PBS at 4 C overnight. Plates were
stored at 4 C and washed once with washing buffer (0.05% Tween-20 in
PBS) before starting the assay. Serum samples were diluted 1:500 in
sample buffer (5% swine serum (Biological Industries, Beit Haemek,
Israel), 0.1% Tween-20 in PBS) and incubated at 37 C for 2 h. After
washing, secondary horseradish peroxidase (HRP) labeled anti-human
IgG (Dako A/S, Glostrup, Denmark) antibody was diluted 1:8000 in
sample buffer and incubated for 1 h at 37 C. TMB One (Kementec So-
lutions A/S, Taastrup, Denmark) was used as substrate and the reaction
was stopped with 0.1 M H2SO4 after 20 min. Absorbance was measured
at 450 nmwith Victor Nivo plate reader (PerkinElmer Inc., Waltham, MS,
USA). Results are expressed as EIA units using seronegative and highly
positive serum samples as standards [43].
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control groups were analyzed with one-way ANOVA. Calculations and
graphs were done using GraphPad Prism 8 software and p-values of
<0.05 were considered statistically significant.2.13. Cytokine fluorescent multiplex bead-based immunoassay (FMIA)
Interferon-gamma (IFN-γ) release to the cell culture medium was
measured using the human Milliplex MAP Kit (HCYTMAG-60 K, Milli-
pore, Billerica, MA, USA), according to manufacturer’s instructions.
Quantification was performed with a Bio-Plex 200® System and Bio-Plex
Manager software version 5.0 (BIO-RAD Laboratories, Hercules, CA,
USA). Each sample was compared to a negative control.
3. Results
3.1. No serological evidence of autoantibodies to OX1 or OX2 receptors in
Pandemrix-vaccinated narcoleptic children or in influenza A virus-infected
patients
We either transduced HuH7 cells with baculoviruses, which were
modified to produce OX1-GFP or OX2-GFP in eukaryotic cells (Fig. 2A), or
transfected the cells with OX1-GFP-V5-His or OX2-GFP-V5-His gene
expression constructs (Fig. 2B). OX1 and OX2 receptors showed similar
membranous expression pattern in Huh7 cells where the expression was
induced by baculovirus transduction or gene transfection. Both OX1 and
OX2 were expressed in cellular membranes and ER-like structures,Fig. 2. Three different vector constructs used to express OX1 and OX2 receptor fusion
expressed in HuH7 cells using a baculovirus-mediated gene delivery method. Pan
respectively, in HuH7 cells. (B) OX1-GFP-V5-His and OX2-GFP-V5-His, under the CMV
HuH7 cells. Panels c and d show the expression pattern of OX1-GFP-V5-His and OX2
receptors, fused to the myc and His tags, were transiently transfected into HuH7 cells
termini of OX1 and OX2 receptors, respectively, in HuH7 cells. The calibration bar a
5
however, OX1 also seemed to form larger granular structures (Fig. 2a-d).
OX1 and OX2 are transmembrane proteins (Fig. 1B) and autoantibodies
against these proteins can be screened by staining OX1-GFP- and OX2-
GFP-producing cells with human sera followed by secondary anti-human
IgG rhodamine conjugate and analyzing the staining patterns with
confocal laser microscopy. Serum specimens were analyzed in 1:25 and
1:100 dilutions to ensure a sensitive detection of also low antibody levels.
None of the analyzed patient/vaccinee sera showed autoantibodies to
OX1 or OX2 receptors (Fig. 3a and b, 4a,b). However, polyclonal rabbit
anti-OX2-specific immunoglobulins readily detected transiently
expressed OX2 gene products in HuH7 cells (Fig. 3d, e and 4d, 4e) as
evidenced with a clear colocalization of GFP (green) and rhodamine-
labeled (red) rabbit anti-OX2 IgG antibodies in confocal microscopy
(Figs. 3 and 4).3.2. No serological evidence of autoantibodies to the isolated N-termini of
OX1 or OX2 receptors in Pandemrix-vaccinated narcoleptic children and
control individuals or in influenza A virus-infected patients
Next, we analyzed the possible presence of autoantibodies to OX2
receptors from the same sera as above using a modified experimental
protocol. We transiently transfected HuH7 cells with expression vectors
encoding the N-terminal parts of human OX1 (amino acids 1–46) or OX2
(amino acids 1–54) receptors fused to C-terminal myc-His-tags. This
enabled us to double stain the cells with patient sera and anti-His im-
munoglobulins, and to analyze the staining patterns with confocal laser
microscopy. We analyzed all 56 sera from narcoleptic children, pairedand deletion proteins. (A) OX1-GFP and OX2-GFP, under a CMV promoter, were
els a and b show the cellular expression pattern of OX1-GFP and OX2-GFP,
promoter in the pcDNA3.1 expression vector, were transiently transfected into
-GFP-V5-His in HuH7 cells, respectively. (C) The N-termini of the OX1 and OX2
. Panels e and f show the intracellular location and expression pattern of the N-
pplies to all images.
Fig. 3. Human sera do not recognize OX1 or OX2 re-
ceptors while rabbit polyclonal anti-OX2 immuno-
globulins recognize OX2 in baculovirus-transduced
HuH7 cells. HuH7 cells, grown on glass coverslips,
were first transiently transduced with baculoviruses
coding for OX1-GFP or OX2-GFP under CMV promoter.
After 24 h, the cells were fixed and stained with 1:25
dilutions of human narcoleptic patient sera, followed
by staining with Texas Red-labeled anti-human im-
munoglobulins (rows a and b) or with 1:200 diluted
rabbit anti-OX2 immunoglobulins, followed by stain-
ing with Texas Red-X-labeled anti-rabbit immuno-
globulins (rows c, d and e) as indicated in the figure.
In the merged images, yellow indicates colocalization
of GFP and rabbit anti-OX2 antibodies. The same
calibration bar applies to all images in a and b, and for
c–e, for the entire row. Panel e represents larger
magnification of stained cells.
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controls as above. Dilutions of 1:25 and 1:100 of the sera were used.
None of these sera showed autoantibodies to OX1 or OX2 receptor N-
terminus (Fig. 5A).
3.3. No detectable autoantibodies to the full-length prepro-orexin in
Pandemrix-vaccinated narcoleptic children, control individuals or influenza
virus-infected patients
We also analyzed possible presence of autoantibodies to the orexin
precursor, prepro-orexin, from the same sera as above. We transiently6
transfected HuH7 cells with cDNA, encoding the full-length 131-aa-long
prepro-orexin, subcloned intomyc-His-tagged expression vector in which
the tags were expressed in the C-terminal end of the molecule. This
enabled us to use double staining with patient sera and anti-His immu-
noglobulins and analyze staining patterns with confocal laser micro-
scopy. We analyzed 46 serum specimens from narcoleptic children,
paired serum specimens from 28 adults and 19 sera from Pandemrix
vaccinated controls as above. The dilution of human sera was 1:25. None
of the analyzed sera showed autoantibodies to the orexin precursor
molecule (Fig. 5B).
Fig. 4. Analysis of IgG antibodies against OX2 in
transiently transfected HuH7 cells. HuH7 cells, grown
on glass coverslips, were first transiently transfected
with OX1-GFP-V5-His or OX2-GFP-V5-His expression
constructs. After 24 h, the cells were fixed and stained
with 1:25 diluted human narcoleptic patient sera,
followed by staining with Texas Red-labeled anti-
human immunoglobulins (rows a and b) or with 1:200
diluted rabbit anti-OX2 immunoglobulins, followed by
staining with Texas Red-X-labeled anti-rabbit immu-
noglobulins (rows c, d and e) as indicated in the figure.
In merged images, yellow indicates colocalization of
GFP and rabbit anti-OX2 antibodies. The same cali-
bration bar applies to all images in a and b, and for
c–e, for the entire row. Panel e represents larger
magnification of stained cells.
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detected by EIA and IFA
We also wanted to analyze, whether narcoleptic patients and controls
had antibodies to some influenza A virus proteins, such as NP, as an
indication of previous suffered influenza A virus infection and/or effi-
cient anti-NP response induced by the Pandemrix vaccine. NP was chosen
as the target viral protein, since it is likely that all individuals develop
antibodies against this protein and it is genetically very stable. We used
both IFA and EIA to determine the IgG antibody levels against NP. In
addition, we used EIA to detect IgG antibody levels against H1N1 antigen
suspension of Pandemrix vaccine.7
In EIA, all analyzed serum specimens had anti-NP and anti-H1N1
antibodies but no activity against GST protein (Fig. 6). Both anti-NP
and anti-H1N1 IgG-antibody levels increased after H1N1pdm09 virus
infection and after receiving Pandemrix vaccine as expected. For IFA, we
transiently transfected HuH7 cells with the influenza A/WSN/33 NP
expression vector and analyzed 20 serum specimens from narcoleptic
patients and controls (Fig. 7). All 20 analyzed sera were strongly anti-NP
antibody positive.
The result allowed us to conclude that influenza A NP and H1N1
antigen suspensions were immunogenic, and the studied sera contained
specific antibodies against influenza virus proteins (Figs. 6 and 7). This
confirmatory analysis indicated that immunofluorescence microscopic
Fig. 5. Human sera do not recognize the N-termini of
OX1 or OX2 receptors or prepro-orexin in transiently
transfected HuH7 cells. (A) HuH7 cells, grown on glass
coverslips, were first transiently transfected with vec-
tors expressing either N-terminal OX1 (1–46)-myc-His
or OX2 (1–54)-myc-His. After 24 h, the cells were fixed
and stained with 1:25 diluted human narcoleptic pa-
tient sera and with 1:200 diluted mouse anti-His im-
munoglobulins followed by staining with Texas Red-
labeled anti-human and FITC-labeled anti-mouse im-
munoglobulins as indicated in the figure (rows a and
b). (B) HuH7 cells were first transiently transfected
with prepro-orexin-myc-His expression vector and
then fixed and stained as above (row a). Colocalization
is visualized as yellow color (merged image). The
same calibration bar applies to all images.
Fig. 6. IgG antibody levels against GST protein (negative control), IAV NP with GST protein and H1N1pdm09 antigen suspension of Pandemrix vaccine determined by
EIA. A) IgG levels in Pandemrix-vaccinated narcoleptic patient serum specimens (n ¼ 56) and in paired serum specimens collected in acute (I; n¼ 28) and convalescent
(II; n ¼ 28) phase of PCR-confirmed H1N1pdm09 virus infection. B) IgG levels in Pandemrix-vaccinated serum specimens collected before (n ¼ 18), 3 weeks after (n ¼
18) and 6 months after (n ¼ 18) vaccination. Significance (p) values are shown between different groups although the groups are not directly comparable for anti-
influenza antibody levels.
K. Melen et al. Journal of Translational Autoimmunity 3 (2020) 100055analysis is a reliable method to study whether human sera have anti-
bodies against given protein structures.3.5. T cell study
Since HLA class II antigen DQB1*06:02 is strongly associated with8
narcolepsy, we analyzed the potential existence of cell-mediated immu-
nity against the extracellular N-terminal epitope spanning from aa 27 to
53 of OX2 (Fig. 1). PBMC samples from six narcoleptic patients and five
controls were stimulated with the core peptide DYDDEEFLRYLWREY (aa
33–47) showing partial homology to influenza A nucleoprotein [28], or
with an OX2 peptide pool including DYDDEEFLRYLWREY and
Fig. 7. Antibodies in sera from influenza virus-
infected patients and narcolepsy patients recognize
influenza A virus NP in NP-expressing HuH7 cells.
HuH7 cells, grown on glass coverslips, were first
transiently transfected with a vector expressing influ-
enza A WSN/33 NP gene. After 24 h, the cells were
fixed and stained with 1:200 diluted rabbit anti-NP
immunoglobulins and 1:100 diluted human sera, fol-
lowed by staining with FITC-labeled anti-rabbit and
Texas Red-labeled anti-human immunoglobulins.
Merge images indicate double staining and colocali-
zation of rabbit anti-NP and human anti-NP anti-
bodies. The same calibration bar applies to all images.
Fig. 8. No cell-mediated immunity against isolated OX2 receptor N-terminal
epitopes. Six Pandemrix-associated NT1 patient and five Pandemrix-vaccinated
healthy control (HC) PBMC samples were stimulated for 6 days with tetanus
toxoid (positive control), the OX2 receptor core peptide DYDDEEFLRYLWREY
(OX2 33–47), or a peptide pool of five 15-mer peptides, covering OX2 (27–53)
epitopes with 12 amino acid overlaps (and including the core peptide DYD-
DEEFLRYLWREY). Secretion of IFN-γ to PBMC culture medium was measured by
FMIA. Results are expressed as the ratio between a stimulated sample and the
corresponding negative control (stimulation indices). Stimulation of PBMC
samples with the OX2 N-terminus core peptide DYDDEEFLRYLWREY or with the
peptide pool failed to induce IFN-γ production.
K. Melen et al. Journal of Translational Autoimmunity 3 (2020) 100055PBMC-produced IFN-γ was analyzed by FMIA. None of the narcoleptic
patients or control showed stimulatory responses to OX2-specific pep-
tides while all samples showed strong cell-mediated responses, i.e. high
stimulatory indices in IFN-γ production in response to stimulation with
tetanus toxoid (Fig. 8).
4. Discussion
All our narcolepsy patients related to Pandemrix vaccination were
classified as narcolepsy type 1 [24]. Genotyping of the patients revealed
them to be HLA DQB1*06:02 positive, which is the strongest genetic
factor predisposing to NT1 [6,7]. NT1 is characterized by the destruction
of hypothalamic orexin-producing neurons, which leads to orexin defi-
ciency in the central nervous system and development of clinical nar-
colepsy. At present, the environmental factors contributing to the
pathophysiology of the disease have remained elusive. Cell-mediated
autoimmunity and/or cytotoxicity caused by cytokines and inflamma-
tory cells have been speculated to lead to the death of orexin-producing
neurons in the hypothalamus [2,44]. Also autoantibodies against many
types of tissues and molecules, including anti-Tribbles homolog 2 anti-
bodies [45,46], anti-ganglioside antibodies [47], anti-neurexin-1 anti-
bodies [47,48], and antibodies against various hypothalamic and
neuronal structures [49] as well as antibodies against OX2 receptor have
been identified [28]. The role of humoral autoimmunity in the onset of
narcolepsy is unclear.
An increased risk to develop NT1 after pH1N1 vaccination has been
linked to European Pandemrix vaccine but not to the Arepanrix vaccine
used in Canada [17,24,34,50]. Vaarala and coworkers suggested that
pandemic influenza vaccine-associated risk could be due to some anti-
genic differences in the H1N1 antigen used in the two vaccines, Pan-
demrix and Arepanrix [32]. The authors showed that the amounts of viral
NP protein and its polymeric form were higher in the Pandemrix than in
the Arepanrix vaccine. They also showed increased antibody responses
against NP in patients positive in the DQB1*06:02 allele [32].
It has been suggested that molecular mimicry and cross-reactivity
between microbial and host proteins may contribute to the develop-
ment of autoimmune diseases such as narcolepsy. Several groups have
tried to detect autoantibodies against orexin receptors. In a limited
number of sera, collected from children and adolescents who developed
narcolepsy after Pandemrix vaccination, Ahmed and co-workers found
antibodies against influenza A virus NP epitope, which cross-reacted with
an epitope within the extracellular N-terminus of the human OX2 re-
ceptor [28]. However, other groups have been unable to confirm these
results fully or at all. Using mass spectrometric analyses, Luo and
co-workers failed to detect OX2-specific cross-reactive autoantibodies in
any of the serum specimens of forty post-Pandemrix narcolepsy cases,
suggesting that OX2-specific autoantibodies are not a characteristic
feature of Pandemrix-associated narcolepsy [29]. Using a cell-based
immunofluorescence method Ciannoccaro and co-workers found only9
low levels of IgG antibodies against OX2 in 3 out of 61 patients with
narcolepsy, suggesting that autoantibodies against OX2 are uncommon in
NT1 patients whose disease is not associated with the Pandemrix vacci-
nation [30].
In the present study, our purpose was to further evaluate the molec-
ular mimicry hypothesis of autoantibodies to OX2 in sera collected from
Pandemrix-vaccinated narcoleptic children and adolescents. In this
analysis immunofluorescence microscopy, with a laser confocal micro-
scopic device, was selected for its sensitivity and specificity. We tran-
siently expressed full-length human OX1 and OX2 receptors or just the N-
terminal extracellular OX1 (amino acids 1–46) and OX2 (amino acids
1–54) receptor domains. HuH7 cells were also transiently transfected
with a prepro-orexin expression construct. The use of chimeric GFP gene
constructs with the full-length receptors enabled us to avoid double
staining and a plausible cross-reactivity due to secondary antibodies. In
double staining experiments we also failed to see any colocalization of
K. Melen et al. Journal of Translational Autoimmunity 3 (2020) 100055patient serum immunoglobulins with His-tagged target molecules.
Both transduced and transfected full-length OX1-GFP and OX2-GFP
expression constructs presented very similar staining patterns, indicating
proper protein folding and likely correct expression of the receptors.
However, short N-terminal OX1-myc-His and OX2-myc-His peptides were
localized mainly into the cell nucleus. Since these molecules are small
they are likely passively translocated into the nucleus.
Analysis of serum specimens from Pandemrix-vaccinated narcoleptic
patients and controls as well as from patients, who suffered from a
laboratory-confirmed H1N1pdm09 infection, failed to reveal any auto-
antibodies against OX2 using IFA. We were, thus, not able to confirm the
results of Ahmed and co-workers, who found antibodies against influenza
NP epitope, which cross-reacted with the N-terminus of human OX2 [28].
Our results are thus in line with the results of Luo and co-workers and
Ciannoccaro and co-workers, who suggested that autoantibodies against
OX2 are not a typical feature in NT1 patients or in post-Pandemrix
autoimmune responses [29,30]. Polyclonal commercially available rab-
bit polyclonal anti-OX2 immunoglobulins very specifically recognized
OX2 in transiently transduced and transfected HuH7 cells, indicating that
our techniques would be specific enough to detect OX2 autoantibodies in
human sera if they had existed. In addition, analysis of anti-NP antibodies
in patient sera with IFA and EIA readily showed antibody responses
against influenza A virus NP and clearly detectable colocalization of
human (patients sera) and rabbit anti-NP antibody staining in confocal
microscopy. We also found no autoimmunity against the full-length
prepro-orexin.
In a limited number of patient PBMCs, we could not demonstrate any
cell-mediated immunity against the N-terminus of OX2. There is recent
evidence that narcoleptic patients show cell-mediated immunity against
Tribbles homolog 2 and especially against the orexin molecules [51].
However, in that study potential autoimmunity against orexin receptors
was not analyzed.
5. Conclusions
In the present study, we found no evidence of humoral immunity
against human OX1 or OX2 orexin receptors or the prepro-orexin mole-
cule in a relatively large collection of serum specimens obtained from
narcolepsy type 1 patients whose disease onset was associated with the
use of Pandemrix vaccine. Thus, we found no evidence that influenza A
virus vaccine antigen would induce cross-reactive antibodies between
influenza virus nucleoprotein and orexin receptors in spite of putative
molecular mimicry between viral NP and human OX2 receptor.Declaration of competing interest
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